可以防止皮层神经元中的端粒缩短,在粉样β诱导的毒性中
Rafael M Themoteo1, Vanessa J R De Paula1,2, Nicole K R Rocha1,2
1Laboratory of Neuroscience (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo 05508-090, SP, Brazil.
NeuroSci
|November 1, 2024
概括
治疗保护了神经元培养物免受粉样β毒性和端粒缩短. 这表明是.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 显示出减弱与阿尔茨海默病 (AD) 相关的神经退行机制的潜力.
- 可能促进神经营养和保护性反应,包括维持端粒长度.
研究的目的:
- 研究预处理对神经元中粉胺β (Aβ) 诱导毒性的保护作用.
- 在Aβ诱导的神经元损伤的背景下,评估对端粒长度的影响.
主要方法:
- 皮层神经元被用化以不同度 (2mM,0.2mM,0.02mM) 治疗七天.
- 在治疗结束前24小时诱导了胺β (Aβ) 毒性.
主要成果:
- 与对照组相比,的预处理显著增加了端粒长度 (120-180%的增量).
- 暴露于Aβ1−42显著降低了神经元培养中的MTT吸收 (33%) 和端粒长度 (83%).
- 防止了Aβ诱导的培养活力丧失和端粒缩短.
结论:
- 有效地保护神经元培养物免受Aβ诱导的毒性.
- 当神经元受到粉样β纤维的挑战时,的预处理可以保持端粒长度和细胞活力.
更多相关视频
06:23Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
7.9K
14:57Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
94.0K
相关概念视频
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Long-term Potentiation
54.8K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
54.8K
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
